Quoin Pharmaceuticals
PublicQuoin Pharmaceuticals is now publicly traded
The data on this page reflects Quoin Pharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Aug 31, 2026
Total Funding Raised
$163.75M
Company Overview
Quoin Pharmaceuticals operates in Healthcare and is based in Ashburn, Virginia. It has raised $163.75M.
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops and commercializes therapeutic products for rare and orphan diseases.
Sector
Healthcare
AI Layer
Non-AI
Quoin Pharmaceuticals Comparables
Compare Quoin Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dermelix Biotherapeutics | 83% | |
| Patagonia Pharmaceuticals, LLC | 78% | |
| Orvida Pharma Ltd. | 77% |
For institutional investors. Book with your work email.
Quoin Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 31, 2026 | ||||
| Private Placement | Oct 14, 2025 | ||||
| Private Placement | Aug 23, 2022 | ||||
| Private Placement | Jan 31, 2018 | ||||
| Private Placement | Sep 11, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Quoin Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| StemPoint Capital LP | Series B |
| Sphera Funds Management | Series B |
| Stonepine Capital Management | Series B |
Quoin Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.